NPAU Stock Chart & Stats
€0.14
>-€0.01(-4.20%)
At close: 4:00 PM EDT
€0.14
>-€0.01(-4.20%)
Day’s Range― - ―
52-Week Range€0.02 - €0.27
Previous CloseN/A
Volume266.00
Average Volume (3M)13.96K
Market Cap
€98.87M
Enterprise Value€51.90M
Total Cash (Recent Filing)€973.59K
Total Debt (Recent Filing)€2.51M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Dec 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding618,007,200
10 Day Avg. Volume7,571
30 Day Avg. Volume13,957
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.75
Price to Sales (P/S)0.00
P/FCF Ratio-11.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.12
Revenue Forecast (FY)€1.86B
Bulls Say, Bears Say
Bulls Say
Narrower LossesLosses narrowing from 2022 indicates some spending discipline and could extend the runway relative to the prior period. However, the company remains unprofitable and has no reported revenue, so this improvement has not yet translated into self-funding or demonstrated commercial earnings.
Improved Cash-Burn ControlLower cash burn than in 2022 is a constructive operating trend and may reduce the pace at which external funding is consumed. Even so, operating and free cash flow remain negative, so the improvement supports efficiency but does not establish durable cash generation.
Defined Therapeutic FocusConcentrating on mental-health and neurological candidates gives the company a defined therapeutic and intellectual-property focus rather than a broad operating model. That specialization can support coherent pipeline development, although the pack does not show commercialization yet.
Bears Say
No Revenue And Persistent LossesThe absence of reported revenue alongside continuing net losses shows that the pipeline has not yet produced a commercial earnings base. Until meaningful commercialization or another revenue source emerges, ongoing investment needs will continue to pressure financial sustainability.
Negative Shareholders’ EquityA persistent equity deficit weakens financial flexibility and raises solvency risk, even though absolute debt is modest. Negative equity can also constrain funding options and leave the company more dependent on external capital to maintain operations and advance its pipeline.
Negative Cash GenerationConsistently negative operating and free cash flow means the business is not currently self-funding its activities. Continued cash consumption increases reliance on external financing, which can limit strategic flexibility and create pressure if capital is not available on acceptable terms.
BetterLife Pharma News
NPAU FAQ
What was BetterLife Pharma’s price range in the past 12 months?
BetterLife Pharma lowest stock price was €0.02 and its highest was €0.27 in the past 12 months.
What is BetterLife Pharma’s market cap?
BetterLife Pharma’s market cap is €98.87M.
When is BetterLife Pharma’s upcoming earnings report date?
BetterLife Pharma’s upcoming earnings report date is Dec 17, 2026 which is in 65 days.
How were BetterLife Pharma’s earnings last quarter?
BetterLife Pharma released its earnings results on Sep 29, 2026. The company reported -€0.008 earnings per share for the quarter.
Is BetterLife Pharma overvalued?
According to Wall Street analysts BetterLife Pharma’s price is currently Overvalued.
Does BetterLife Pharma pay dividends?
BetterLife Pharma does not currently pay dividends.
What is BetterLife Pharma’s EPS estimate?
BetterLife Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BetterLife Pharma have?
BetterLife Pharma has 618,007,200 shares outstanding.
What happened to BetterLife Pharma’s price movement after its last earnings report?
BetterLife Pharma reported an EPS of -€0.008 in its last earnings report. Following the earnings report the stock price went up 15.294%.
Which hedge fund is a major shareholder of BetterLife Pharma?
Currently, no hedge funds are holding shares in DE:NPAU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BetterLife Pharma
BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-based technologies, designed to engage the immune system in combating viral infections. Its active development pipeline includes BETR-001, intended for major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another key asset, BETR-002, is being advanced to address benzodiazepine dependency, anxiety, and spasticity. Further in development are MM-003 for COVID-19 and other respiratory viral infections; MM-001, a topical intravaginal cream for HPV-induced cervical intraepithelial neoplasia; and AP-002, designated for cancer treatment. BetterLife Pharma Inc. maintains a research collaboration with the University of California San Diego, focusing on preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. Headquartered in Vancouver, Canada, the company was founded in 2002 and was formerly known as Pivot Pharmaceuticals Inc. before adopting the name BetterLife Pharma Inc. in December 2019.
Technical Analysis
COSCIENS Biopharma
―
PharmaTher Holdings Ltd
―
Marvel Biosciences Corp
―
Doseology Sciences
―
PharmAla Biotech Holdings, Inc.
―